Boehringer Ingelheim extends "one stop shop" service with new fill and finish capabilities

Ingelheim - To round off its full-service capabilities for clients, Boehringer Ingelheim is expanding its capacities and capabilities in fill & finish for biopharmaceuticals at their state-of-the-art facility in Biberach, Germany, with a new filling line. The new line is available as of today for contract filling of liquid and lyo vials from 0,5 ml- 100 ml. The expansion to a combination line for single and double chamber catridges will be up and running in Q4 2012. To meet the customers’ demand for clinical and commercial scale filling the batch sizes range from 6.000 – 110.000 ml for vials and 50.000 – 100.000 ml for carpoules.

The new line with isolator technique represents one further step in Boehringer Ingeheim’s “one stop shop” for contract development and manufacturing of biopharmaceuticals. With this state of the art technology Boehringer Ingelheim offers further excellence and solutions in the contract manufacturing business to its customers in addition to the existing capacities for lyophilization, vial filling and filling in pre-filled syringes. Customers’ can rely on Boehringer Ingelheim either as a single supplier or they can also enter flexible at any step in the development.

“As a leader in its field, Boehringer Ingelheim has supported pharmaceutical companies in the successful launch of many biologic drugs” says Simon Sturge, Corporate Senior Vice President Biopharmaceuticals.“I believe that this further expansion will benefit our customers by receiving high quality drug substance and drug product from one source with very convenient applications which bring an even higher benefit for the patients.”

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
Today, Boehringer Ingelheim is one of the world’s leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer Ingelheim delivers services for pre-clinical development up to global market supply with a strong commitment to its customers at its global manufacturing facilities for mammalian cell culture and microbial fermentation. Boehringer Ingelheim has brought 19 molecules to market and has many years of experience in multiple molecule classes such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules and plasmid DNA. Furthermore, high-titer platform technologies for new antibody mimetic formats such as scaffold proteins and antibody fragments are available for the manufacture of customer products.